The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis

被引:8
|
作者
Lubrini, Genny [1 ]
Rios Lago, Marcos [2 ,3 ]
Perianez, Jose A. [4 ]
Tallon Barranco, Antonio [1 ]
De Dios, Consuelo [5 ]
Fernandez-Fourier, Mireya [1 ]
Diez Tejedor, Exuperio [1 ]
Frank Garcia, Ana [1 ]
机构
[1] Univ Autonoma Madrid, IdiPAZ Hlth Res Inst, La Paz Univ Hosp, Dept Neurol, Madrid, Spain
[2] Hosp Beata Maria Ana, Brain Damage Serv, Madrid, Spain
[3] UNED, Dept Basic Psychol 2, Madrid, Spain
[4] Univ Complutense Madrid, Dept Basic Psychol 2, Madrid, Spain
[5] Univ Autonoma Madrid, IdiPAZ Hlth Res Inst, La Paz Univ Hosp, Dept Psychiat, Madrid, Spain
关键词
Depression; information processing speed; multiple sclerosis; neuropsychological assessment; Reaction Time; visual search; MAJOR DEPRESSION; WORKING-MEMORY; SPEED; PERFORMANCE; IMPAIRMENT; RELIABILITY; INVENTORY; ATTENTION; CAPACITY; SUBTYPES;
D O I
10.1177/1352458516661047
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Slowness of information processing has been suggested as a fundamental factor modulating cognitive impairment in multiple sclerosis (MS). However, the contribution of depressive symptoms (DS) to slowness remains unclear. One of the most accepted hypotheses on the impact of depression on the general population suggests that depression interferes only with tasks requiring high cognitive demands. However, no studies have investigated if the same pattern occurs in MS. Objective: The aim of this study was to determine the profile of the contribution of DS to slowness. Methods: Four Reaction Time (RT) tasks requiring an increasing level of cognitive demands were administered to 35 relapsing remitting MS patients with DS, 33 MS patients without DS, 17 depressed non-MS patients and 27 controls. Results: MS patients without DS obtained longer RTs than controls in all the tasks. On the contrary, depressed non-MS patients were slower than controls only in the most demanding task. Finally, MS patients with DS were slower than MS patients without DS not only in the most demanding task but also in the task requiring a lower level of cognitive demands. Conclusion: The contribution of DS to slowness depends on the level of cognitive demands. However, its impact on MS is more deleterious than on the general population.
引用
收藏
页码:1607 / 1615
页数:9
相关论文
共 50 条
  • [31] Prevalence and prognostic value of prodromal symptoms in relapsing-remitting multiple sclerosis
    Kania, Karolina
    Ambrosius, Wojciech
    Dyczkowska, Klara
    Kozubski, Wojciech
    Kalinowska-Lyszczarz, Alicja
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2023, 57 (03) : 289 - 296
  • [32] Neurobiological mechanisms underlying emotional processing in relapsing-remitting multiple sclerosis
    Passamonti, Luca
    Cerasa, Antonio
    Liguori, Maria
    Gioia, Maria Cecilia
    Valentino, Paola
    Nistico, Rita
    Quattrone, Aldo
    Fera, Francesco
    BRAIN, 2009, 132 : 3380 - 3391
  • [33] Effect of deep gray matter atrophy on information processing speed in early relapsing-remitting multiple sclerosis
    Naghavi, Saba
    Ashtari, Fereshteh
    Adibi, Iman
    Shaygannejad, Vahid
    Ramezani, Neda
    Pourmohammadi, Ahmad
    Davanian, Fariba
    Karimi, Zahra
    Khaligh-Razavi, Seyed-Mahdi
    Sanayei, Mehdi
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 71
  • [34] Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis
    Syed, Yahiya Y.
    DRUGS, 2021, 81 (01) : 157 - 168
  • [35] Autohemotherapy for relapsing-remitting multiple sclerosis
    Mubaidin, AF
    Horani, KA
    Dehayyat, MA
    Shehab, M
    Abu-Ruman, IA
    Shurbaji, AA
    Kurdi, A
    Hiari, M
    Khakish, M
    Harahsheh, O
    Dabbas, M
    NEUROLOGY, 2001, 56 (08) : A75 - A75
  • [36] Relapsing-remitting tumefactive multiple sclerosis
    Selkirk, SM
    Shi, J
    MULTIPLE SCLEROSIS, 2005, 11 (06): : 731 - 734
  • [37] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Guo, Rui
    Zhang, Fubo
    Zhang, Chao
    Dong, Shuai
    Zhou, Hongyu
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [38] Thalamic neurodegeneration in relapsing: Remitting multiple sclerosis
    Cifelli, AI
    Wylezinska, M
    Jezzard, P
    Palace, J
    Alecci, M
    Matthews, P
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (08): : 1177 - 1177
  • [39] Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis
    Yahiya Y. Syed
    Drugs, 2021, 81 : 157 - 168
  • [40] Ozanimod for the treatment of relapsing remitting multiple sclerosis
    Rasche, Ludwig
    Paul, Friedemann
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (18) : 2073 - 2086